Picture your Future. Save for it by earning 1.5% on a 1-year Term Deposit Account! Learn more.

Blue Whale Update: H1 2022 Performance Update

Stephen Yiu - Blue Whale Fund Manager


Stephen Yiu is the Chief Investment Officer at Blue Whale Capital and Lead Manager of the Blue Whale Growth Fund.

Stephen co-founded Blue Whale Capital with Peter Hargreaves, co-founder of Hargreaves Lansdown, in 2016. The Blue Whale Growth Fund was launched in September 2020 and is a long-only global equity fund focusing on developed markets.

Stephen adopts a high conviction, active approach based on
bottom-up, fundamental research.

The first half of 2022 saw inflation fears of late 2021 come to a head. Accordingly, global equity markets saw increased volatility, with a mark down across the board. Traditional value stocks, which had fared well in 2021, also saw their share prices coming off, with a few exceptions, largely in the oil and gas sector.   

An area that was particularly hit was the tech sector, in which Blue Whale has a significant portion of the Fund invested. While lower quality businesses thrived under pandemic conditions (Peloton, Deliveroo for example), inflated share prices not backed by company fundamentals saw investors flee as the world emerged from lockdowns. However, investor nerves led not only to lower quality businesses seeing a price downgrade, but also contagion spreading to higher quality tech stocks as an indiscriminate sell-off materialised.  

In the first half, the T-Acc USD shares fell 37.2%, the T-Acc EUR shares fell 31.7% and the T-Acc GBP shares fell 30.1%, compared to the IA Global Average which fell 14.1%. This underperformance over the period was largely due to the higher technology exposure in the portfolio versus the Global sector as a whole.   

Two of the larger individual detractors to performance fall into this sector – Nvidia (maker of high-capability processors) and Atlassian (collaborative working tools). The share price decline of these two companies can be attributed to a valuation reset based on higher interest rates – with no material adverse news or change to company fundamentals, we remain confident in our investment thesis. The other main detractor was Sartorius (biomedicine). Again, the investment thesis remains intact, and we view the share price decline primarily as a symptom of macro-economic malaise. 

Leading contributors to fund performance were Nintendo (video games) and Mastercard and Visa (payment networks and systems). With the release of a raft of new games and sales of the popular Switch console continuing apace, the Nintendo share price recovered some lost ground in the first few months of the year. Mastercard and Visa, whilst decidedly volatile during H1 2022, benefitted from the return of cross-border travel. The two payment titans also offer what we believe to be the purest available inflation hedge as they continue to take their percentage on the inflated price of goods and services bought using their ubiquitous payments systems.   

New additions to the portfolio were North American railroad operators Canadian National Railway and Union Pacific. With high margins and strong cash generation and a secular move towards repatriating supply chains, these companies offer a defensive play given the uncertainty of inflation and the spectre of recession. In addition, they offer an interesting ESG angle given the sustainability and efficiency of utilising railroad transport over that of truck haulage and air delivery.   

Key disposals were PayPal and Meta (Facebook). In the case of PayPal, concerns over company strategy relating to acquisitions and increased competition in the sector encouraged us to sell our position. Meta, having changed its name from Facebook, showed their hand when it came to investment in the metaverse, subsequently leading to concerns over a deterioration in its business quality due to an apparent significant investment in this area. Following the disposal of Amazon at the end of 2021, the only FAANG still standing in the portfolio is a small holding in Alphabet (Google).   

Looking forward, whilst the first half of the year has been characterised by inflation and interest rate risk, we anticipate that the inflation narrative will taper off whilst we head towards greater recession risk. As the cost of capital is likely to remain high, the Blue Whale portfolio of companies maintains a net-cash balance sheet, with high gross margins and strong pricing power. The relative valuation of high-quality tech businesses in the portfolio is attractive when compared to those sectors which have done comparatively well in the first half – sectors such as consumer staples which now trade at a significant premium to the market. We therefore hope to see a return to outperformance on a relative basis at least in the coming months. 


Blue Whale Growth Fund is manufactured by Blue Whale Capital LLP and represented in Malta by MeDirect Bank (Malta) plc.


Blue Whale Key Risks & Disclaimers:

The Blue Whale Growth Fund was launched in September 2020. All references to actions before this date relate to the LF Blue Whale Growth Fund.  Information on the LF Blue Whale Growth Fund is provided for comparison purposes only; it is a UK UCITS which is not registered for sale in nor is it promoted to investors in the EEA.  Whilst the investment objectives and charges are not identical, both funds are run on the same investment process.

Please note that the information provided in this article is not to be construed as advice and any views we express on holdings do not constitute investment recommendations and must not be viewed as such. If you are unsure as to the suitability of an investment for your circumstances, please seek independent financial advice. Investments can go down in value as well as up so you may get back less than you invested. Your capital is at risk. Past performance is not a guide to future performance.Blue Whale Capital LLP is authorised and regulated by the UK Financial Conduct Authority.

There are significant risks associated with investment in the Fund referred to herein. Investment in the Fund is intended for investors who understand and can accept the risks associated with such an investment including potentially a substantial or complete loss of their investment.

Past performance is not a guide to future performance. The value of investments and any income derived from them can go down as well as up and the value of your investment may be volatile and be subject to sudden and substantial falls.

Investment in a Fund with exposure to emerging markets involves risk factors and special considerations which may not be typically associated with investing in more developed markets. Political or economic change and instability may be more likely to occur and have a greater effect on the economies and markets of emerging countries. Adverse government policies, taxation, restrictions on foreign investment and on currency convertibility and repatriation, currency fluctuations and other developments in the laws and regulations of emerging countries in which investment may be made, including expropriation, nationalisation or other confiscation could result in loss to the Fund.

Income from investments may fluctuate. Changes in rates of exchange may have an adverse effect on the value, price or income of investments. Fund charges may be applied in whole or part to capital, which may result in capital erosion. The Authorised Corporate Director may apply a dilution adjustment as detailed in the Prospectus. The Fund is not traded on an exchange or recognised market.

The foregoing list of risk factors is not complete, and reference should be made to the Fund’s Prospectus, KIID and application form.

MeDirect Disclaimers:

This information has been accurately reproduced, as received from Blue Whale Growth Fund. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest in a mutual fund should always be based upon the details contained in the Prospectus and Key Investor Information Document (KIID), which may be obtained from MeDirect Bank (Malta) plc.

Join MeDirect today to access the tools you need to put your money to work on your own terms.

Latest news articles

Staying dynamic in our strategic views
All News

BlackRock Commentary: Staying dynamic in our strategic views

BlackRock anticipates that the new macroeconomic environment, characterized by increased volatility, will lead to more frequent valuation changes across asset classes. While short-term outcomes may not always be influenced by valuations, they remain significant in the long run.

Experience better Banking

The sooner you start managing your money, your way, using the best-in-class tools, the sooner you’ll see results. 

Sign up and open your account for free, within minutes.



We strive to ensure a streamlined account opening process, via a structured and clear set of requirements and personalised assistance during the initial communication stages. If you are interested in opening a corporate account with MeDirect, please complete an Account Opening Information Questionnaire and send it to corporate@medirect.com.mt.

For a comprehensive list of documentation required to open a corporate account please contact us by email at corporate@medirect.com.mt or by phone on (+356) 2557 4444.